

THE FIRST AND ONLY IV IBUPROFEN FOR PAIN AND FEVER



RAISING THE LEVEL OF PATIENT CARE



THE ONLY FDA APPROVED IV FEVER TREATMENT¹⁻⁴

- Significant temperature reduction after just one dose
- Observed treatment effect remained throughout dosing period
- Clinical data in hospitalized febrile patients support safety and efficacy in critically- and non-critically ill patients*

THE LEVEL OF SAFETY THAT IBUPROFEN DELIVERS

- In key clinical trials of over 900 patients
 - No significant differences in renal, cardiac, or bleeding adverse events vs placebo were seen^{1,2,3}
 - Gastrointestinal disorders were no more common in patients treated with CALDOLOR than in those receiving placebo^{1,2,3}

FOR CLINICAL INFORMATION, VISIT WWW.CALDOLOR.COM.

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Risk

- Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use
- CALDOLOR is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery

Gastrointestinal Risk

- NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Events can occur at any time without warning symptoms. Elderly patients are at greater risk

IMPORTANT SAFETY INFORMATION

CALDOLOR should be used with caution in patients with congestive heart failure, kidney impairment, at risk of blood clots, and in those who have a history of ulcers or gastrointestinal bleeding. When used in such patients, attention to using the lowest effective dose for the shortest time period is important to reduce the risk of serious adverse events. Ibuprofen has been associated with high blood pressure, serious skin reactions, and serious allergic reactions.

The most common adverse events reported in the controlled clinical trials were nausea, flatulence, vomiting, and headache.

Please see [full Prescribing Information](#), including Boxed Warning.

CALDOLOR is indicated in adults for the management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, and reduction of fever.

*Critically ill defined as patients requiring mechanical ventilation and/or vasopressors.

Reference: 1. Caldolor [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; 2009.

2. Morris P, et al. A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. *Crit Care* 2010;14:R125.

3. Krudsood S, et al. Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia. *Am J Trop Med Hyg* 2010;83(1):51-55.

4. Bernard GR, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. *N Engl J Med*. 1997 Mar 27;336(13):912-8.

CALDOLOR is a registered trademark of [Cumberland Pharmaceuticals Inc.](#)



©2010 Cumberland Pharmaceuticals Inc., Nashville, TN September 2010 WWW1471110

CALDOLOR[®]
(ibuprofen) Injection
Ibuprofen advances to IV